Desafíos en el proceso hacia la Unión Monetaria Europea

Abstract

N6-Methyladenosine (m⁶A) has attracted growing interest among scholars as an important regulator of mRNA expression. Although the significant role of m⁶A in multiple biological processes (like proliferation and growth of cancers) has been comprehensively described, an analysis of its possible role in stomach adenocarcinoma (STAD) of tumor immune microenvironment (TIME) remains lacking. The data for RNA expression, single nucleotide polymorphism (SNP), and copy number variation (CNV) were downloaded from The Cancer Genome Atlas (TCGA). Subsequently, 23 m⁶A regulators were curated, with patients being clustered into three m⁶A subtypes and m⁶A-related gene subtypes. Furthermore, they were compared based on overall survival (OS). This study also evaluates the association between m⁶A regulators and immune as well as response to the treatment. According to the TCGA-STAD cohort, three m⁶A clusters conformed to three phenotypes, immune-inflamed, immune-dessert, and immune-excluded, respectively. Patients who displayed lower m⁶A scores presented better overall survival outcomes. The GEO cohort demonstrated that those with a low m⁶A score had obvious general survival benefits and clinical advantages. Low m⁶A scores can carry the enhanced neoantigen loads, triggering an immune response. Meanwhile, three anti-PD-1 cohorts have confirmed the value of predicting survival outcomes. The results of this study indicate that m⁶A regulators are associated with TIME, and the m⁶A score is an efficient prognostic biomarker and predictive indicator for immunotherapy and chemotherapeutics. Moreover, comprehensive evaluations of m⁶A regulators in tumors will broaden our comprehension of TIME, efficiently guiding enhancing explorations on immunotherapy and chemotherapy strategies for STAD.